Korean J Gastroenterol.  2017 Aug;70(2):111-113. 10.4166/kjg.2017.70.2.111.

Treatment of Chronic Hepatitis C Patients Who Do Not Respond to Direct Acting Antivirals

• Kim JH

• KMID: 2391370
• DOI: http://doi.org/10.4166/kjg.2017.70.2.111

Abstract

No abstract available.

MeSH Terms

Antiviral Agents*
Hepatitis C, Chronic*
Hepatitis, Chronic*
Antiviral Agents

Reference

1. Naggie S, Muir AJ. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med. 2017; 68:345–358.

2. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016; 64:486–504.

3. Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat. 2015; 22:1011–1019.

4. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015; 373:2599–2607.

5. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015; 373:2608–2617.

6. Taylor JG, Appleby T, Barauskas O, et al. P0899: Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol. 2015; 62:Suppl 2. S681.

7. Kirby B, Yang J, Yang C, et al. P0861: Evaluation of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 in healthy volunteers. J Hepatol. 2015; 62:Suppl 2. S663.

8. Rodriguez-Torres M, Glass S, Hill J, et al. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016; 23:614–622.

9. Gane EJ, Schwabe C, Hyland RH, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology. 2016; 151:448–456.e1.

10. Lawitz E, Reau N, Hinestrosa F, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial. Gastroenterology. 2016; 151:893–901.e1.

11. Gane EJ, Kowdley KV, Pound D, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology. 2016; 151:902–909.

12. Aghemo A, Buti M. Hepatitis C therapy: game over! Gastroenterology. 2016; 151:795–798.

13. Kim YS. Updated treatment of chronic hepatitis C. Korean J Med. 2017; 92:24–35.

14. Global health sector strategy on viral hepatitis 2016-2021. [Internet]. Geneva: World Health Organization (WHO);2016. 06. updated 2016 Jun 30. cited 2017 Jul 29. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.

15. Rosen HR. “Hep C, where art thou”: what are the remaining (fundable) questions in hepatitis C virus research. Hepatology. 2017; 65:341–349.

16. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016; 22:76–139.

17. Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol. 2016; 22:432–438.

18. Lawitz E, Poordad F, Wells J, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017; 65:1803–1809.

19. Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016; 12:1197–1209.